Alzheimer's collaboration revenue — Total Revenue
Biogen Alzheimer's collaboration revenue — Total Revenue increased by 39.3% to $59.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 80.3%, from $33.00M to $59.50M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates successful market penetration and commercial scaling of the Alzheimer's therapeutic portfolio, while a decrease may signal competitive pressure or slower-than-expected adoption.
Detailed definition
This metric represents the total gross revenue recognized by the company from collaborative arrangements specifically fo...
Peer comparison
Comparable to revenue from co-promotion or profit-sharing agreements in the biopharmaceutical industry, often benchmarked against other specialty neurology or oncology collaboration segments.
biib_segment_alzheimer_s_collaboration_revenue_total_revenueHistorical Data
| Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $0.00 | -$18.90M | -$20.70M | $2.80M | $11.80M | $18.60M | $33.00M | $54.90M | $42.70M | $59.50M |
| QoQ Change | — | — | — | -9.5% | +113.5% | +321.4% | +57.6% | +77.4% | +66.4% | -22.2% | +39.3% |
| YoY Change | — | — | — | — | +114.8% | +157.0% | — | >999% | +365.3% | +129.6% | +80.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's alzheimer's collaboration revenue — total revenue?
- Biogen (BIIB) reported alzheimer's collaboration revenue — total revenue of $59.50M in Q1 2026.
- How has Biogen's alzheimer's collaboration revenue — total revenue changed year-over-year?
- Biogen's alzheimer's collaboration revenue — total revenue increased by 80.3% year-over-year, from $33.00M to $59.50M.
- What does alzheimer's collaboration revenue — total revenue mean?
- The total revenue generated from the company's collaborative partnerships for Alzheimer's disease treatments.